DZ
DefZone.Net

Kien thuc cong nghe & giai tri

Wiki Article

Enrico Mini

Nguồn dữ liệu từ Wikipedia, hiển thị bởi DefZone.Net

Xem trên WikipediaBài ngẫu nhiên khác
Enrico Mini
OccupationsOncologist, pharmacologist, and academic
Academic background
EducationM.D.,
Specialty Degree., Oncology
Ph.D., Pharmacology and Toxicology
Alma materUniversity of Florence
University of Modena
Academic work
InstitutionsUniversity of Florence

Enrico Mini is an oncologist, pharmacologist, and academic. He is an emeritus professor at the University of Florence.

Mini's research interests include cancer pharmacology, tumor drug resistance, and the pharmacogenomics of anticancer therapies, with a focus on colorectal cancer, other gastrointestinal neoplasms, leukemia, and lymphoma. He was the director of the Unit of Translational Oncology at Careggi University Hospital and the head of the Laboratory of Cancer Pharmacology and Chemotherapy at the University of Florence.

Education

[edit]

Mini earned his M.D. from the University of Florence in 1977.[1] In 1980, he subsequently received his specialty degree in Oncology from the University of Modena, followed by his Ph.D. in Pharmacology and Toxicology in 1988 from the University of Florence.[2]

Career

[edit]

Mini's academic career includes his appointment as a research scientist at the Departments of Pharmacology and Medicine of the Yale University School of Medicine from 1981 to 1984. Later, he was appointed as a lecturer at the University of Siena from 1983 to 1987 and then began working as a lecturer at the University of Ferrara in 1988, a position he held until 1992. He was subsequently appointed as an associate professor of pharmacology at the University of Florence from 1992 to 2001,[2] and then as professor of Pharmacology from 2001 to 2008.[1] He was appointed as the professor of Medical Oncology at the University of Florence in 2008 and later as an emeritus professor there.[3]

Mini was the chairman of the Cancer Section of the International Society of Chemotherapy from 2007 to 2013.[1] Between 2011 and 2020, he was appointed as director of the Specialty School of Medical Oncology at the University of Florence.[2] He held these positions until his retirement in 2022, after which he continued as the scientific lead of funded research projects. Since 2018, he has been the coordinator of the Oncological Pharmacology Working Group of the Italian Society of Pharmacology.[4][5]

Research

[edit]

Mini's research contributed to clarifying the mechanisms of methotrexate (MTX), a chemotherapeutic and immunosuppressive agent that exerts its effects by binding to the folic acid target enzyme dihydrofolate reductase (DHFR), a mechanism widely recognized in cancer therapy.[6] whereby methotrexate functions as an antifolate agent by targeting dihydrofolate reductase (DHFR), which catalyzes the transformation of dihydrofolate (DHF) into tetrahydrofolate (THF).[7][8] In related research, it was demonstrated that polyglutamylation of methotrexate contributes to its selective cytotoxic effect.[9]

Mini proposed that administering MTX before 5-FU produces synergy, since the polyglutamated MTX can replace 5,10-CH2-THF in the ternary complex.[10] He further indicated that alterations in the balance of polyglutamylated MTX forms often lead to the development of drug resistance.[11] His studies pointed out that the recognition of leucovorin as a biomodulator of 5-fluorouracil (5-FU) cytotoxicity in preclinical experiments prompted a surge of phase I and II clinical investigations.[12]

Mini, through his research, highlighted the negative role of P-gp, an ABC transporter with extensive substrate specificity in anticancer therapy for leukemia and other solid tumors.[13] He then strategically modified anticancer drugs to reduce P-gp-mediated efflux[14] and underlined the need for creating drugs that are non-P-gp substrates to counter cancer resistance hindrances.[15] In collaborative study, he explored reversing multidrug resistance (MDR) in DOX-resistant human colorectal adenocarcinoma cells (Lo Vo/Dx) through long-term treatment with an equimolar mixture of three unmodified ODNs targeting adjacent sites on MDR1 mRNA, delivered via the synthetic cationic lipid (DOTAP).[16] He also showed that a combination of antisense oligonucleotides could downregulate mdr-1 mRNA in the highly doxorubicin-resistant LoVo/Dx subline of human adenocarcinoma LoVo cells.[17] He went on to identify specific RNA-based targets in different cancers, including those implicated in colorectal cancer (CRC).[18] He further highlighted the role of histone structure modification in causing cancer as well as its progression, while also asserting that histone methylation can lead to gene repression and activation, whereas acetylation is consistently linked with gene activation.[19]

In another line of research, Mini explored the potential of Au-based complexes for their use as metallodrugs in cancer.[20] He also highlighted Et3PAuI's demonstrated activity against platinum-resistant ovarian cancer cells, while exhibiting cross-resistance in ovarian cancer cells resistant to auranofin. He has been named in the Stanford University-Elsevier-developed World’s Top 2% Scientists List 2024 and 2025.[21][22]

Selected articles

[edit]
  • Pizzorno, G; Mini, E; Coronnello, M; McGuire, J J; Moroson, B A; Cashmore, A R; Dreyer, R N; Lin, J T (1988). "Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug". Cancer Research. 48 (8): 2149–2155. PMID 2450647.
  • McCloskey, D E; McGuire, J J; Russell, C A; Rowan, B G; Bertino, J R; Pizzorno, G; Mini, E (1991). "Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines". Journal of Biological Chemistry. 266 (10): 6181–6187. doi:10.1016/S0021-9258(18)38101-8. PMID 2007575.
  • Mazzei, T; Mini, E; Novelli, A; Periti, P (1993). "Chemistry and mode of action of macrolides". Journal of Antimicrobial Chemotherapy. 31 (Suppl C): 1–9. doi:10.1093/jac/31.suppl_c.1. PMID 7683018.
  • Arcangeli, A; Bianchi, L; Becchetti, A; Faravelli, L; Coronnello, M; Mini, E; Olivotto, M; Wanke, E (1995). "A novel inward-rectifying K+ current with a cell-cycle dependence governs the resting potential of mammalian neuroblastoma cells". The Journal of Physiology. 489 (Pt 2): 455–471. doi:10.1113/jphysiol.1995.sp021065. PMC 1156772. PMID 8847640.
  • Messori, L; Abbate, F; Marcon, G; Orioli, P; Fontani, M; Mini, E; Mazzei, T; Carotti, S; O'Connell, T; Zanello, P (2000). "Gold(III) complexes as potential antitumor agents: solution chemistry and cytotoxic properties of some selected gold(III) compounds". Journal of Medicinal Chemistry. 43 (19): 3541–3548. doi:10.1021/jm990492u. PMID 11000008.
  • Mini, E; Nobili, S; Caciagli, B; Landini, I; Mazzei, T (2006). "Cellular pharmacology of gemcitabine". Annals of Oncology. 17 (Suppl 5): v7–v12. doi:10.1093/annonc/mdj941. PMID 16807468.
  • Nobili, Stefania; Mini, Enrico; Landini, Ida; Gabbiani, Chiara; Casini, Angela; Messori, Luigi (2010). "Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies". Med Res Rev. 30 (3): 550–580. doi:10.1002/med.20168. PMID 19634148.
  • Mini, Enrico; Lapucci, Andrea; Perrone, Gabriele; D'Aurizio, Romina; Napoli, Cristina; Brugia, Marco; Landini, Ida; Tassi, Renato (2019). "RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy". International Journal of Cancer. 145 (9): 2580–2593. doi:10.1002/ijc.32326. PMID 30973654.
  • Lavacchi, Daniele; Landini, Ida; Perrone, Gabriele; Roviello, Giandomenico; Mini, Enrico; Nobili, Stefania (2022). "Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: Still an unmet challenge". Pharmacology & Therapeutics. 229 107924. doi:10.1016/j.pharmthera.2021.107924. PMID 34175369.

References

[edit]
  1. ^ a b c "Editorial Board Member". Cancer Drug Resistance. Retrieved September 11, 2025.
  2. ^ a b c "ENRICO MINI CURRICULUM VITAE" (PDF). top italian scientists. Retrieved September 11, 2025.
  3. ^ "Enrico Mini". CercaChi UniFI. Retrieved December 8, 2025.
  4. ^ "Oncological Pharmacology Working Group". Italian Society of Pharmacology (in Italian). Retrieved 6 January 2026.
  5. ^ "Enrico Mini - VILLA DONATELLO". villadonatello. Retrieved December 18, 2025.
  6. ^ Peng, Lun (2022). Sequence-defined carriers for drug and nucleic acid delivery (Thesis). Ludwig-Maximilians-Universität München. doi:10.5282/edoc.30409.[page needed]
  7. ^ Mauritz, Robert; Peters, Godefridus J. (November 2008). "Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo". Cancer Chemotherapy and Pharmacology. 62 (6): 938. doi:10.1007/s00280-008-0683-0. PMID 18283461.
  8. ^ Ortenberg, R.; Rozenblatt-Rosen, O. (March 2000). "The extremely halophilic archaeon Haloferax volcanii has two very different dihydrofolate reductases". Mol Microbiol. 35 (6): 1501. doi:10.1046/j.1365-2958.2000.01815.x. PMID 10760149.
  9. ^ Fabre, I.; Fabre, G.; Goldman, I. D. (1984). "Polyglutamylation, an important element in methotrexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cells in vitro". Cancer Research. 44 (8): 3190–3195. PMID 6204743.
  10. ^ Isacoff, William H.; Borud, Katrina (1997). "Chemotherapy for the Treatment of Patients with Metastatic Colorectal Cancer: An Overview". World Journal of Surgery. 21 (7): 748–762. doi:10.1007/S002689900301. PMID 9276707.
  11. ^ Szabó, Ildikó; Orbán, Erika; Schlosser, Gitta; Hudecz, Ferenc; Bánóczi, Zoltán (2016). "Cell-penetrating conjugates of pentaglutamylated methotrexate as potential anticancer drugs against resistant tumor cells". European Journal of Medicinal Chemistry. 115: 361–368. doi:10.1016/j.ejmech.2016.03.034. PMID 27031212.
  12. ^ Ab Mutalib, Nurul-Syakima; Md Yusof, Najwa F.; Abdul, Shafina-Nadiawati; Jamal, Rahman (2017). "Pharmacogenomics DNA Biomarkers in Colorectal Cancer: Current Update". Frontiers in Pharmacology. 8 736: 2. doi:10.3389/fphar.2017.00736. PMC 5644034. PMID 29075194.
  13. ^ Vinogradov, Serguei; Wei, Xin (2012). "Cancer stem cells and drug resistance: the potential of nanomedicine". Nanomedicine (Lond). 7 (4): 597–615. doi:10.2217/nnm.12.22. PMC 3376090. PMID 22471722.
  14. ^ Waghray, Deepali; Zhang, Qinghai (2018). "Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment". Journal of Medicinal Chemistry. 61 (12): 5108–5121. doi:10.1021/acs.jmedchem.7b01457. PMC 6281405. PMID 29251920.
  15. ^ Van Vuuren, Rustelle Janse; Visagie, Michelle H.; Theron, Anne E.; Joubert, Annie M. (2015). "Antimitotic drugs in the treatment of cancer". Cancer Chemotherapy and Pharmacology. 76 (6): 1101–1112. doi:10.1007/s00280-015-2903-8. PMC 4648954. PMID 26563258.
  16. ^ Binkhathlan, Ziyad; Lavasanifar, Afsaneh (2013). "P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives". Current Cancer Drug Targets. 13 (3): 326–346. doi:10.2174/15680096113139990076. PMID 23369096.
  17. ^ Byrne, D.; Daly, C. (1998). "Use of ribozymes and antisense oligodeoxynucleotides to investigate mechanisms of drug resistance". Cytotechnology. 27 (1–3): 122. doi:10.1023/A:1008052401952. PMC 3449559. PMID 19002787.
  18. ^ Wang, Wen-Tao; Han, Cai; Sun, Yu-Meng; Chen, Tian-Qi; Chen, Yue-Qin (2019). "Noncoding RNAs in cancer therapy resistance and targeted drug development". Journal of Hematology & Oncology. 12 (1): 5. doi:10.1186/s13045-019-0748-z. PMC 6556047. PMID 31174564.
  19. ^ Blondy, Sabrina; David, Valentin; Verdier, Mireille; Mathonnet, Muriel; Perraud, Aurélie; Christou, Niki (2020). "5-Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes". Cancer Science. 111 (9): 3142–3154. doi:10.1111/cas.14532. PMC 7469786. PMID 32536012.
  20. ^ Hussaini, Sunusi Y.; Haque, Rosenani A.; Razali, Mohd R. (2019). "Recent progress in silver(I)-, gold(I)/(III)- and palladium(II)-N-heterocyclic carbene complexes: A review towards biological perspectives". Journal of Organometallic Chemistry. 882: 96–111. doi:10.1016/j.jorganchem.2019.01.003.
  21. ^ "Mini, Enrico". World's Top 2% Scientists. Retrieved 6 January 2026.
  22. ^ Abdalbari, Farah H.; Telleria, Carlos M. (2021). "The gold complex auranofin: New perspectives for cancer therapy". Discover Oncology. 12 (1) 42. doi:10.1007/s12672-021-00439-0. PMC 8777575. PMID 35201489.
[edit]